6-(1-吡咯烷基)吡啶-3-甲醛 | 261715-39-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(1-吡咯烷基)吡啶-3-甲醛
• 中文别名: 6-(1-吡咯烷并)吡啶-3-甲醛；6-(1-吡咯烷)烟酰甲醛；6-吡咯-1-炔烟碱醛
• 英文名称: 6-(pyrrolidin-1-yl)nicotinaldehyde
• 英文别名: 6-(1-pyrrolidinyl)nicotinaldehyde；6-pyrrolidin-1-ylpyridine-3-carbaldehyde
• CAS: 261715-39-3
• 化学式: C₁₀H₁₂N₂O
• mdl: MFCD06200881
• 分子量: 176.218
• InChiKey: FFFAXGTZBUMKTI-UHFFFAOYSA-N

物化性质

• 熔点：
  89 °C
• 沸点：
  358.1±27.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物和空气

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Name:	6-(1-Pyrrolidinyl)nicotinaldehyde Material Safety Data Sheet
Synonym:	None Known
CAS:	261715-39-3

Section 1 - Chemical Product MSDS Name:6-(1-Pyrrolidinyl)nicotinaldehyde Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
261715-39-3	6-(1-Pyrrolidinyl)nicotinaldehyde	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38 42

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin. May cause sensitization by inhalation.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. Harmful if inhaled. May cause respiratory sensitization.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 261715-39-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81-82 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12N2O
Molecular Weight: 176.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 261715-39-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-(1-Pyrrolidinyl)nicotinaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
R 42 May cause sensitization by inhalation.
Safety Phrases:
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 261715-39-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 261715-39-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 261715-39-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(1-吡咯烷基)吡啶-3-甲醛 在 正丁基锂 、 1,3-双(二苯基膦)丙烷 、 palladium diacetate 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (E)-3-fluoro-2-hydroxy-5-(2-(6-(pyrrolidin-1-yl)pyridin-3-yl)vinyl)benzaldehyde
  参考文献：
  名称：

  [EN] COMPOUNDS AS MODULATORS OF TLR2 SIGNALING
  [FR] COMPOSÉS UTILISÉS EN TANT QUE MODULATEURS DE SIGNALISATION TLR2

  摘要：

  本公开涉及化合物、包含这种化合物的药物组合物，以及利用这些化合物进行治疗方法或用于治疗与炎症信号传导过程相关的炎症性疾病和某些神经系统疾病的药物。这些神经系统疾病与炎症信号传导过程有关，包括但不限于蛋白质错折。

  公开号：

  WO2019191189A1
• 作为产物：
  描述：

  四氢吡咯 、 6-氯烟醛 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 以79.9 %的产率得到6-(1-吡咯烷基)吡啶-3-甲醛
  参考文献：
  名称：

  一种咪唑并噻二唑类化合物及其制备方法与应用

  摘要：

  本发明涉及放射性药物化学领域及临床核医学技术领域，具体涉及一种咪唑并噻二唑类化合物及其制备方法与应用。所述化合物如结构通式(I)所示。使用合适的放射性同位素对其进行标记后，此类化合物及其衍生物可对脑内的α‑突触核蛋白聚集体进行核医学显像，从而辅助包括帕金森症、路易体痴呆、多系统萎缩和一些罕见疾病在内的突触核蛋白病的临床诊断。#imgabs0#

  公开号：

  CN118496243A

文献信息

• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• KYNURENINE PRODUCTION INHIBITOR
  申请人：Amishiro Nobuyoshi

  公开号：US20110237584A1

  公开（公告）日：2011-09-29

  Provided is a kynurenine production inhibitor comprising a nitrogen-containing heterocyclic compound represented by formula (I): (wherein R 50 and R 51 may be the same or different and each represent a hydrogen atom or the like, G 1 and G 2 may be the same or different and each represent a nitrogen atom or the like, X represents formula (III): (wherein m 1 and m 2 may be the same or different and each represent an integer of 0 or 1, Y represents an oxygen atom or the like, and R 6 and R 7 may be the same or different and each represent a hydrogen atom or the like), R 1 represents optionally substituted lower alkyl or the like, R 2 represents a hydrogen atom or the like, and R 3 represents optionally substituted lower alkyl or the like), and the like.

  提供的是一种色氨酸代谢抑制剂，包括由式(I)表示的含氮杂环化合物：（其中R50和R51可以相同也可以不同，每个代表氢原子或类似物，G1和G2可以相同也可以不同，每个代表氮原子或类似物，X表示式(III)：（其中m1和m2可以相同也可以不同，每个代表0或1的整数，Y表示氧原子或类似物，R6和R7可以相同也可以不同，每个代表氢原子或类似物），R1表示可选择地取代的低碳烷基或类似物，R2表示氢原子或类似物，R3表示可选择地取代的低碳烷基或类似物），等等。
• [EN] BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS BICYCLIQUES PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES
  申请人：KYORIN SEIYAKU KK

  公开号：WO2013003383A1

  公开（公告）日：2013-01-03

  Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文披露了新型桥环双环化合物，以及它们的药用盐、水合物和前药。还披露了包含这些化合物的组合物，制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。所披露的化合物、其药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗细菌感染及相关疾病和症状。
• [EN] NEW BRADYKININ B1 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR DE LA BRADYKININE B1
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2010020556A1

  公开（公告）日：2010-02-25

  The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式（I）的化合物，其中R1、R1a、R1b、R2、R3以及X、X1、X2、X3的含义如描述和权利要求中所述。所述化合物可用作Bradykinin B1拮抗剂。该发明还涉及制药组合物、该类化合物的制备以及作为药物的生产和使用。
• [EN] NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE SPIROPIPÉRIDINE PROLYLCARBOXYPEPTIDASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011137024A1

  公开（公告）日：2011-11-03

  Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

  结构式（I）化合物是脯氨酰羧肽酶（PrCP）的抑制剂。本发明的化合物对于预防和治疗与PrCP酶活性相关的疾病非常有用，如异常代谢，包括肥胖、糖尿病、代谢综合征、肥胖相关疾病和糖尿病相关疾病。